Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
Open Access
- 2 December 2019
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 38 (2) , 233-242
Abstract
Background Innovations in hepatitis C virus (HCV) therapy included in traditional comparative evaluations focus on sustained virologic response (SVR) without addressing challenges patients report beyond virologic cure. This study aims to evaluate the cost-effectiveness of HCV drug therapy with a patient-centered approach. Methods An individual-based Markov model was constructed using guidance from a stakeholder advisory board (SAB), a patient Delphi panel, and published literature to evaluate direct-acting antivirals (DAAs) compared to no treatment. The United States (US) health sector and societal perspectives were considered for 10- and 20-year time horizons. Inputs for treatment costs and effectiveness reflect a generic regimen. Indirect costs used for the societal model included estimates from self-reported productivity in a matched-control sample. Beyond the traditional quality-adjusted life-year (QALY) health outcome, this study included two novel measures developed from the Delphi panel and SAB: infected life-years and workdays missed. All costs were measured in 2018 US dollars. Results Health sector costs and QALYs were higher in the treatment group in both 10- and 20-year models. Total infected life-years and workdays missed were reduced in the treatment group for both models. When costs of absenteeism, presenteeism, and patient/caregiver time were included, the DAA intervention was cost-saving at both 10 and 20 years. Health sector results were sensitive to drug costs and utility estimates for post-SVR health states. Societal results were sensitive to presenteeism estimates and drug costs. Conclusion Treatment was cost-effective from a health sector perspective and cost-saving when including non-health costs such as patient/caregiver time and productivity.Keywords
Funding Information
- Patient-Centered Outcomes Research Institute (7709720-A)
This publication has 55 references indexed in Scilit:
- The Burden of Untreated Hepatitis C Virus Infection: A US Patients’ PerspectiveDigestive Diseases and Sciences, 2012
- Patient time costs and out‐of‐pocket costs in hepatitis CLiver International, 2012
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis CHepatology, 2011
- Defining Comparative Effectiveness ResearchMedical Care, 2010
- Trends in Organ Donation and Transplantation in the United States, 1999-2008American Journal of Transplantation, 2010
- Healthcare Rationing by ProxyPharmacoEconomics, 2010
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patientsJournal of Hepatology, 2004
- Willingness to Pay for a Quality-adjusted Life YearMedical Decision Making, 2000
- An Algorithm for the Grading of Activity in Chronic Hepatitis CHepatology, 1996